Next, whether the antitumor efficacy of the in situ cancer vaccine was mediated by immune effector cells (Fig. 7A) in the 4T1 mouse model via depleting CD8+ and/or CD4+ T cells was evaluated. The gene discussed is CD4; the disease is cancer.